Toll Free: 1-888-928-9744

Ocular Hypertension - Pipeline Review, H1 2016

Published: Mar 22, 2016 | Pages: 127 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ocular Hypertension - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Ocular Hypertension - Pipeline Review, H1 2016', provides an overview of the Ocular Hypertension pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ocular Hypertension
- The report reviews pipeline therapeutics for Ocular Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Ocular Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Ocular Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Ocular Hypertension

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Ocular Hypertension Overview 10 Therapeutics Development 11 Pipeline Products for Ocular Hypertension - Overview 11 Pipeline Products for Ocular Hypertension - Comparative Analysis 12 Ocular Hypertension - Therapeutics under Development by Companies 13 Ocular Hypertension - Therapeutics under Investigation by Universities/Institutes 15 Ocular Hypertension - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Ocular Hypertension - Products under Development by Companies 19 Ocular Hypertension - Products under Investigation by Universities/Institutes 21 Ocular Hypertension - Companies Involved in Therapeutics Development 22 Aerie Pharmaceuticals, Inc. 22 Allergan Plc 23 Amakem NV 24 Asahi Kasei Pharma Corp. 25 Bausch & Lomb Incorporated 26 Can-Fite BioPharma Ltd. 27 D. Western Therapeutics Institute, Inc. 28 F. Hoffmann-La Roche Ltd. 29 Inotek Pharmaceuticals Corporation 30 Kowa Company, Ltd. 31 Lee's Pharmaceutical Holdings Limited 32 NicOx S.A. 33 Ocular Therapeutix, Inc. 34 Ono Pharmaceutical Co., Ltd. 35 Otsuka Holdings Co., Ltd. 36 pSivida Corp. 37 Sanofi 38 Santen Pharmaceutical Co., Ltd. 39 Senju Pharmaceutical Co., Ltd. 40 Sylentis S.A.U. 41 ViSci Ltd. 42 Ocular Hypertension - Therapeutics Assessment 43 Assessment by Monotherapy Products 43 Assessment by Combination Products 44 Assessment by Target 45 Assessment by Mechanism of Action 47 Assessment by Route of Administration 49 Assessment by Molecule Type 51 Drug Profiles 53 (carteolol hydrochloride + latanoprost) - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 (dorzolamide hydrochloride + latanoprost) - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 (latanoprost + netarsudil mesylate) - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 (latanoprost + trabodenoson) - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 (tafluprost + timolol maleate) - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 AMA-0076 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 ATS-8535 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 bamosiran - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 bimatoprost - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 bimatoprost SR - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 DE-117 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 H-1129 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 latanoprost - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 latanoprost - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 latanoprost SR - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 latanoprost SR - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 latanoprost SR - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 latanoprostene bunod - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 levobetaxolol hydrochloride - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 NCX-470 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 NCX-667 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 netarsudil mesylate - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 ONO-9054 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 OPA-6566 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 piclidenoson - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 RG-4929 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 ripasudil - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 RO-5093151 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 SAR-366234 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 SNJ-1656 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 trabodenoson - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 travoprost SR - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Ocular Hypertension - Recent Pipeline Updates 96 Ocular Hypertension - Dormant Projects 114 Ocular Hypertension - Discontinued Products 116 Ocular Hypertension - Product Development Milestones 117 Featured News & Press Releases 117 Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting 117 Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week 117 Feb 17, 2016: Aerie Pharmaceuticals Reports Positive Rhopressa QD (netarsudil ophthalmic solution) 0.02% 12 Month Interim Safety Results for Rocket 2 118 Feb 16, 2016: Ocular Therapeutix Announces Phase 3 Clinical Development Plan for OTX-TP, an Innovative Therapy for Glaucoma and Ocular Hypertension 119 Oct 22, 2015: Ocular Therapeutix Reports on Topline Results of Phase 2b Glaucoma Clinical Trial 120 Oct 01, 2015: New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension 122 Sep 24, 2015: Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of Rhopressa 122 Sep 22, 2015: Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO (latanoprostene bunod) 123 Sep 21, 2015: Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial of Roclatan 124 Sep 16, 2015: Aerie Pharmaceuticals Reports Positive Rhopressa Phase 3 Efficacy Results 125 Appendix 126 Methodology 126 Coverage 126 Secondary Research 126 Primary Research 126 Expert Panel Validation 126 Contact Us 126 Disclaimer 127
List of Tables
Number of Products under Development for Ocular Hypertension, H1 2016 11 Number of Products under Development for Ocular Hypertension - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2016 21 Ocular Hypertension - Pipeline by Aerie Pharmaceuticals, Inc., H1 2016 22 Ocular Hypertension - Pipeline by Allergan Plc, H1 2016 23 Ocular Hypertension - Pipeline by Amakem NV, H1 2016 24 Ocular Hypertension - Pipeline by Asahi Kasei Pharma Corp., H1 2016 25 Ocular Hypertension - Pipeline by Bausch & Lomb Incorporated, H1 2016 26 Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd., H1 2016 27 Ocular Hypertension - Pipeline by D. Western Therapeutics Institute, Inc., H1 2016 28 Ocular Hypertension - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 29 Ocular Hypertension - Pipeline by Inotek Pharmaceuticals Corporation, H1 2016 30 Ocular Hypertension - Pipeline by Kowa Company, Ltd., H1 2016 31 Ocular Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 32 Ocular Hypertension - Pipeline by NicOx S.A., H1 2016 33 Ocular Hypertension - Pipeline by Ocular Therapeutix, Inc., H1 2016 34 Ocular Hypertension - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 35 Ocular Hypertension - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 36 Ocular Hypertension - Pipeline by pSivida Corp., H1 2016 37 Ocular Hypertension - Pipeline by Sanofi, H1 2016 38 Ocular Hypertension - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016 39 Ocular Hypertension - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2016 40 Ocular Hypertension - Pipeline by Sylentis S.A.U., H1 2016 41 Ocular Hypertension - Pipeline by ViSci Ltd., H1 2016 42 Assessment by Monotherapy Products, H1 2016 43 Assessment by Combination Products, H1 2016 44 Number of Products by Stage and Target, H1 2016 46 Number of Products by Stage and Mechanism of Action, H1 2016 48 Number of Products by Stage and Route of Administration, H1 2016 50 Number of Products by Stage and Molecule Type, H1 2016 52 Ocular Hypertension Therapeutics - Recent Pipeline Updates, H1 2016 96 Ocular Hypertension - Dormant Projects, H1 2016 114 Ocular Hypertension - Dormant Projects (Contd..1), H1 2016 115 Ocular Hypertension - Discontinued Products, H1 2016 116


List of Figures
Number of Products under Development for Ocular Hypertension, H1 2016 11 Number of Products under Development for Ocular Hypertension - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Products, H1 2016 18 Assessment by Monotherapy Products, H1 2016 43 Assessment by Combination Products, H1 2016 44 Number of Products by Top 10 Targets, H1 2016 45 Number of Products by Stage and Top 10 Targets, H1 2016 45 Number of Products by Top 10 Mechanism of Actions, H1 2016 47 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 47 Number of Products by Routes of Administration, H1 2016 49 Number of Products by Stage and Routes of Administration, H1 2016 49 Number of Products by Molecule Types, H1 2016 51 Number of Products by Stage and Molecule Types, H1 2016 51

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecast

Read More...

Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is ant

Read More...

Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive t

Read More...

Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to mo

Read More...

Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global dem

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify